Clioquinol / Hydrocortisone Topical Dosage
Applies to the following strengths: 3%-1%; 3%-0.5%; 3%-0.5% with emollients
Usual Adult Dose for:
Usual Pediatric Dose for:
Additional dosage information:
Usual Adult Dose for Dermatitis
Apply a thin layer topically to the affected area(s) 2 to 4 times a day or as directed
Comments: This product has not been found by the US FDA to be safe and effective and the product labeling has not been approved.
Uses: Based on a review of this drug by the National Academy of Sciences-National Research Council and/or other information, FDA has classified the indications as follows:
- Possibly effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis; intertrigo
Usual Adult Dose for Eczema
Apply a thin layer topically to the affected area(s) 2 to 4 times a day or as directed
Comments: This product has not been found by the US FDA to be safe and effective and the product labeling has not been approved.
Uses: Based on a review of this drug by the National Academy of Sciences-National Research Council and/or other information, FDA has classified the indications as follows:
- Possibly effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis; intertrigo
Usual Adult Dose for Pruritus
Apply a thin layer topically to the affected area(s) 2 to 4 times a day or as directed
Comments: This product has not been found by the US FDA to be safe and effective and the product labeling has not been approved.
Uses: Based on a review of this drug by the National Academy of Sciences-National Research Council and/or other information, FDA has classified the indications as follows:
- Possibly effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis; intertrigo
Usual Pediatric Dose for Dermatitis
2 years or older: Apply a thin layer topically to the affected area(s) 2 to 4 times a day or as directed
Comments:
- This product has not been found by the US FDA to be safe and effective and the product labeling has not been approved.
- Administration of topical corticosteroids to children should be limited to the lowest effective dose for the shortest duration possible.
- Chronic corticosteroid therapy may interfere with growth and development in pediatric patients.
Uses: Based on a review of this drug by the National Academy of Sciences-National Research Council and/or other information, FDA has classified the indications as follows:
- Possibly effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis; intertrigo
Usual Pediatric Dose for Eczema
2 years or older: Apply a thin layer topically to the affected area(s) 2 to 4 times a day or as directed
Comments:
- This product has not been found by the US FDA to be safe and effective and the product labeling has not been approved.
- Administration of topical corticosteroids to children should be limited to the lowest effective dose for the shortest duration possible.
- Chronic corticosteroid therapy may interfere with growth and development in pediatric patients.
Uses: Based on a review of this drug by the National Academy of Sciences-National Research Council and/or other information, FDA has classified the indications as follows:
- Possibly effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis; intertrigo
Usual Pediatric Dose for Pruritus
2 years or older: Apply a thin layer topically to the affected area(s) 2 to 4 times a day or as directed
Comments:
- This product has not been found by the US FDA to be safe and effective and the product labeling has not been approved.
- Administration of topical corticosteroids to children should be limited to the lowest effective dose for the shortest duration possible.
- Chronic corticosteroid therapy may interfere with growth and development in pediatric patients.
Uses: Based on a review of this drug by the National Academy of Sciences-National Research Council and/or other information, FDA has classified the indications as follows:
- Possibly effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis; intertrigo
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
Precautions
Safety and efficacy have not been established in patients younger than 2 years.
Consult WARNINGS section for additional precautions.
Dialysis
Data not available
Other Comments
Administration advice:
- For external use only.
- Avoid use in or around the eyes.
Storage requirements:
- Protect from freezing.
General:
- May produce false-positive ferric chloride test results for phenylketonuria (PKU) if iodochlorhydroxyquin is present in the neonate's diaper or urine.
- Pediatric therapy continuing for longer than 2 weeks and consisting of doses in excess of 2 applications per day (with low-potency corticosteroids) should be carefully evaluated by the physician; especially important if the medication is applied to more than 5% to 10% of the body surface or if an occlusive dressing is used.
- A tight-fitting diaper or one covered with plastic pants may constitute an occlusive dressing.
Monitoring:
- Endocrine: Urinary free cortisol and adrenocorticotropic hormone (ACTH) stimulation tests may be helpful in evaluating hypothalamic-pituitary-adrenal (HPA) axis suppression.
Patient advice:
- Report any signs of local adverse reactions especially under occlusive dressing.
More about clioquinol / hydrocortisone topical
- Check interactions
- Compare alternatives
- Reviews (1)
- Side effects
- During pregnancy
- Drug class: topical steroids with anti-infectives
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
